CollPlant Biotechnologies Ltd. (CLGN): Price and Financial Metrics

CollPlant Biotechnologies Ltd. (CLGN)

Today's Latest Price: $14.90 USD

0.31 (2.12%)

Updated Jan 25 4:00pm

Add CLGN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

CLGN Stock Summary

  • CollPlant Biotechnologies Ltd's stock had its IPO on January 31, 2018, making it an older stock than just 8.86% of US equities in our set.
  • CLGN's price/sales ratio is 13.75; that's higher than the P/S ratio of 86.53% of US stocks.
  • With a year-over-year growth in debt of -63.5%, CollPlant Biotechnologies Ltd's debt growth rate surpasses merely 4.33% of about US stocks.
  • Stocks that are quantitatively similar to CLGN, based on their financial statements, market capitalization, and price volatility, are LMNL, GNMK, MXL, PI, and LJPC.
  • Visit CLGN's SEC page to see the company's official filings. To visit the company's web site, go to

CLGN Stock Price Chart Interactive Chart >

Price chart for CLGN

CLGN Price/Volume Stats

Current price $14.90 52-week high $16.32
Prev. close $14.59 52-week low $6.00
Day low $14.51 Volume 20,200
Day high $15.00 Avg. volume 36,040
50-day MA $10.25 Dividend yield N/A
200-day MA $9.47 Market Cap 84.48M

CollPlant Biotechnologies Ltd. (CLGN) Company Bio

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

CLGN Latest News Stream

Event/Time News Detail
Loading, please wait...

CLGN Latest Social Stream

Loading social stream, please wait...

View Full CLGN Social Stream

Latest CLGN News From Around the Web

Below are the latest news stories about CollPlant Biotechnologies Ltd that investors may wish to consider to help them evaluate CLGN as an investment opportunity.

How Should Investors Feel About CollPlant Biotechnologies' (NASDAQ:CLGN) CEO Remuneration?

Yehiel Tal has been the CEO of CollPlant Biotechnologies Ltd. ( NASDAQ:CLGN ) since 2010, and this article will examine...

Yahoo | December 3, 2020

CollPlant Biotechnologies Reports Third Quarter (Q3) 2020 Financial Results and Provides Business Update

CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the third quarter ended September 30, 2020 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See "Use of Non-GAAP Measures" below.

Yahoo | December 1, 2020

CollPlant Announces Early Development Program of Antiviral Agent for Potential Treatment of COVID-19 Patients

CollPlant (NASDAQ: CLGN) a regenerative medicine company, today announced its development program of an antiviral agent for potential treatment of COVID-19 patients. In-vitro early results of CollPlant's formulations showed significant inhibition of avian coronavirus infectivity. CollPlant's formulations designed for the potential treatment of COVID-19 patients are based on CollPlant's proprietary recombinant human type I collagen (rhCollagen) imbedded with silver nanoparticles (AgNP).

Yahoo | November 10, 2020

If You Had Bought CollPlant Biotechnologies (NASDAQ:CLGN) Stock A Year Ago, You Could Pocket A 92% Gain Today

The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...

Yahoo | October 9, 2020

CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant

REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a…

PR Newswire | September 21, 2020

Read More 'CLGN' Stories Here

CLGN Price Returns

1-mo N/A
3-mo 111.80%
6-mo 65.37%
1-year 45.06%
3-year N/A
5-year N/A
YTD 38.35%
2020 88.95%
2019 35.71%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8738 seconds.